TABLE OF CONTENTS
1 INTRODUCTION 54
1.1 OBJECTIVES OF THE STUDY 54
1.2 MARKET DEFINITION 54
1.3 OVERVIEW 54
1.4 CURRENCY AND PRICING 57
1.5 LIMITATIONS 57
1.6 MARKETS COVERED 57
2 MARKET SEGMENTATION 60
2.1 MARKETS COVERED 60
2.2 GEOGRAPHICAL SCOPE 61
2.3 YEARS CONSIDERED FOR THE STUDY 61
2.4 DBMR TRIPOD DATA VALIDATION MODEL 62
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 65
2.6 MULTIVARIATE MODELLING 66
2.7 MARKET APPLICATION COVERAGE GRID 67
2.8 PRODUCT LIFELINE CURVE 68
2.9 DBMR MARKET POSITION GRID 69
2.10 SECONDARY SOURCES 70
2.11 ASSUMPTIONS 70
3 EXECUTIVE SUMMARY 71
4 U.S. CHRONIC PANCREATITIS TESTING MARKET 74
4.1 CHRONIC PANCREATITIS 74
4.2 LABORATORY TESTING 74
4.3 CHRONIC PANCREATITIS DIAGNOSE 74
4.4 PANCREATIC FUNCTION TESTS 76
4.4.1 INDIRECT PANCREATIC FUNCTION TESTS 76
4.4.2 DIRECT PANCREATIC FUNCTION TESTS 76
5 PREMIUM INSIGHTS 78
5.1 PESTEL MODEL 79
5.2 PORTER'S FIVE FORCES 80
5.3 EPIDEMIOLOGY 81
6 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, INDUSTRY INSIGHTS 82
7 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, REGULATIONS 83
8 MARKET OVERVIEW 84
8.1 DRIVERS 86
8.1.1 GROWTH IN THE PREVALENCE OF PANCREATIC CANCER 86
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN PANCREATIC DIAGNOSTICS 86
8.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 87
8.1.4 INCREASE IN AWARENESS REGARDING PANCREATIC CANCER 87
8.2 RESTRAINTS 88
8.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF PANCREATIC CANCER DIAGNOSTIC PRODUCTS 88
8.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF PANCREATIC CANCER 88
8.3 OPPORTUNITIES 89
8.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR PANCREATIC CANCER 89
8.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 90
8.3.3 GOVERNMENT INITIATIVES TOWARD PANCREATIC CANCER DIAGNOSTICS 90
8.4 CHALLENGES 91
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 91
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 91
9 IMPACT OF COVID-19 92
9.1 OVERVIEW 92
9.2 DEMAND SURGE FOR MEDICAL DIAGNOSTIC 92
9.3 GROWTH IN GOVERNMENT SPENDING ON HEALTHCARE 92
9.4 STRATEGIC INITIATIVES BY KEY PLAYERS 93
9.5 INCREASE IN THE PRICE OF TESTS KITS AND REAGENTS 93
10 OUTLOOK AND TREND OF THE MARKET AFTER COVID -19 94
11 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TEST TYPE 95
11.1 OVERVIEW 96
11.2 IMAGING TEST 99
11.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 100
11.2.2 MAGNETIC RESONANCE IMAGING (MRI) 100
11.2.3 MR CHOLANGIOPANCREATOGRAPHY 101
11.2.4 MR ANGIOGRAPHY (MRA) 101
11.3 ULTRASOUND 101
11.3.1 ABDOMINAL ULTRASOUND 101
11.3.2 ENDOSCOPIC ULTRASOUND (EUS) 101
11.4 CHOLANGIOPANCREATOGRAPHY 101
11.4.1 MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY (MRCP) 102
11.4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) 102
11.4.3 PRECUTANEOUS TRANSHEPTIC CHOLANGIOPANCREATOGRAPHY (PTC) 102
11.5 POSITRON EMISSION TOMOHRAPHY (PET) 102
11.6 OTHERS 102
11.7 BIOPSY 102
11.8 CT-GUIDED NEEDLE BIOPSY 103
11.9 FINE NEEDLE ASPIRATION (FNA) 103
11.10 CORE NEEDLE BIOPSY 104
11.11 OTHERS 104
11.12 BLOOD TEST 104
11.13 LIVER FUNCTION TEST 105
11.14 TUMOR MARKER 105
11.14.1 CA 19-9 BIOMARKER TEST 105
11.14.2 CARCINOEMBROYNIC ANTIGEN (CEA) TEST 105
11.14.3 CA 50 MARKER TEST 105
11.14.4 OTHERS 105
11.15 OTHERS 106
11.16 GENOMIC TEST 106
11.17 OTHERS 106
12 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 107
12.1 OVERVIEW 108
12.2 STAGE IV 111
12.3 STAGE III 111
12.4 STAGE II 112
12.4.1 STAGE IIA 112
12.4.2 STAGE IIB 112
12.5 STAGE I 113
12.5.1 STAGE IB 113
12.5.2 STAGE IA 113
12.6 STAGE 0 114
13 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 115
13.1 OVERVIEW 116
13.2 EXOCRINE TUMORS 119
13.2.1 INSTRUMENT-BASED PRODUCTS 120
13.2.2 PLATFORM-BASED PRODUCTS 120
13.2.3 KITS AND REAGENTS 120
13.2.4 OTHER CONSUMABLES 120
13.3 NEUROENDOCRINE TUMORS 120
13.3.1 INSTRUMENT-BASED PRODUCTS 121
13.3.2 PLATFORM-BASED PRODUCTS 121
13.3.3 KITS AND REAGENTS 121
13.3.4 OTHER CONSUMABLES 121
14 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY PRODUCT 122
14.1 OVERVIEW 123
14.2 INSTRUMENT-BASED PRODUCTS 126
14.2.1 IMAGING 127
14.2.2 BIOPSY 127
14.3 PLATFORM-BASED PRODUCTS 127
14.3.1 NEXT-GENERATION SEQUENCING 128
14.3.2 MICROARRAYS 128
14.3.3 PCR 128
14.3.4 OTHERS 128
14.4 KITS AND REAGENTS 128
14.4.1 CA19-9 PANCREATIC CANCER TEST KITS 129
14.4.1.1 ELISA TEST KITS 130
14.4.1.2 CASETTE TEST KITS 130
14.4.1.3 OTHERS 130
14.4.2 CEA PANCREATIC CANCER TEST KITS 130
14.4.2.1 ELISA TEST KITS 130
14.4.2.2 CASETTE TEST KITS 130
14.4.2.3 OTHERS 130
14.5 OTHERS 131
15 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 132
15.1 OVERVIEW 133
15.2 FLUORESCENT IN SITU HYBRIDIZATION 136
15.3 NEXT GENERATION SEQUENCING 136
15.4 FLUORIMMUNOASSAY 137
15.5 COMPARATIVE GENOMIC HYBRIDIZATION 137
15.6 IMMUNOHISTOCHEMICAL 138
15.7 OTHERS 138
16 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY APPLICATION 139
16.1 OVERVIEW 140
16.2 SCREENING 143
16.2.1 INSTRUMENT-BASED PRODUCTS 143
16.2.2 PLATFORM-BASED PRODUCTS 143
16.2.3 KITS AND REAGENTS 143
16.2.4 OTHER CONSUMABLES 144
16.3 DIAGNOSTIC AND PREDICTIVE 144
16.3.1 INSTRUMENT-BASED PRODUCTS 145
16.3.2 PLATFORM-BASED PRODUCTS 145
16.3.3 KITS AND REAGENTS 145
16.3.4 OTHER CONSUMABLES 145
16.4 PROGNOSTIC 145
16.4.1 INSTRUMENT-BASED PRODUCTS 146
16.4.2 PLATFORM-BASED PRODUCTS 146
16.4.3 KITS AND REAGENTS 146
16.4.4 OTHER CONSUMABLES 146
16.5 RESEARCH 146
16.5.1 INSTRUMENT-BASED PRODUCTS 147
16.5.2 PLATFORM-BASED PRODUCTS 147
16.5.3 KITS AND REAGENTS 147
16.5.4 OTHER CONSUMABLES 147
17 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY END USER 148
17.1 OVERVIEW 149
17.2 HOSPITALS 152
17.3 DIAGNOSTIC CENTERS 152
17.4 CANCER RESEARCH CENTERS 153
17.5 ACADEMIC INSTITUTES 153
17.6 AMBULATORY SURGICAL CENTERS 153
17.7 OTHERS 154
18 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 155
18.1 OVERVIEW 156
18.2 DIRECT TENDER 159
18.3 RETAIL SALES 159
18.4 OTHERS 159
19 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET, BY REGION 160
19.1 OVERVIEW 161
19.2 U.S. 161
19.3 SOUTHERN U.S. 163
19.3.1 FLORIDA 171
19.3.2 TEXAS 178
19.3.3 NORTH CAROLINA 185
19.3.4 GEORGIA 193
19.3.5 VIRGINIA 201
19.3.6 TENNESSEE 209
19.3.7 REST OF SOUTHERN U.S. 216
19.4 WESTERN U.S. 217
19.4.1 ILLINOIS 228
19.4.2 OHIO 239
19.4.3 MICHIGAN 250
19.4.4 INDIANA 261
19.4.5 MISSOURI 272
19.4.6 MINNESOTA 283
19.4.7 REST OF WESTERN U.S. 294
19.5 MID-WESTERN U.S. 295
19.5.1 CALIFORNIA 303
19.5.2 WASHINGTON 311
19.5.3 ARIZONA 319
19.5.4 COLORADO 327
19.5.5 OREGON 335
19.5.6 NEVADA 343
19.5.7 REST OF MID-WESTERN U.S. 351
19.6 NORTH-EASTERN U.S. 352
19.6.1 NEW YORK 360
19.6.2 PENNSYLVANIA 368
19.6.3 NEW JERSEY 376
19.6.4 MASSACHUSETTS 384
19.6.5 MARYLAND 392
19.6.6 CONNECTICUT 400
19.6.7 REST OF NORTH-EASTERN U.S. 408
20 U.S. PANCREATIC CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 409
20.1 COMPANY SHARE ANALYSIS: EUROPE 409
21 SWOT ANALYSIS 410
22 GLOBAL PANCREATIC CANCER DIAGNOSTICS MARKET 411
22.1 F. HOFFMANN- LA ROCHE LTD 411
22.1.1 COMPANY SNAPSHOT 411
22.1.2 SWOT 412
22.1.3 REVENUE ANALYSIS 412
22.1.4 PRODUCT PORTFOLIO 413
22.1.5 RECENT DEVELOPMENT 413
22.2 KONINKLIJKE PHILIPS N.V. 414
22.2.1 COMPANY SNAPSHOT 414
22.2.2 REVENUE ANALYSIS 414
22.2.3 PRODUCT PORTFOLIO 415
22.2.4 RECENT DEVELOPMENTS 415
22.3 CANON MEDICAL SYSTEMS CORPORATION 416
22.3.1 COMPANY SNAPSHOT 416
22.3.2 REVENUE ANALYSIS 416
22.3.3 PRODUCT PORTFOLIO 417
22.3.4 RECENT DEVELOPMENT 417
22.4 GRAIL 418
22.4.1 COMPANY PROFILE 418
22.4.2 PRODUCT PORTFOLIO 418
22.4.3 RECENT DEVELOPMENT 418
22.5 SIEMENS HEALTHCARE GMBH 419
22.5.1 COMPANY SNAPSHOT 419
22.5.2 REVENUE ANALYSIS 419
22.5.3 PRODUCT PORTFOLIO 420
22.5.4 RECENT DEVELOPMENT 420
22.6 AGILENT TECHNOLOGIES, INC. 421
22.6.1 COMPANY PROFILE 421
22.6.2 REVENUE ANALYSIS 421
22.6.3 PRODUCT PORTFOLIO 422
22.6.4 RECENT DEVELOPMENT 422
22.7 BIOLOGICAL DYNAMICS 423
22.7.1 COMPANY SNAPSHOT 423
22.7.2 SWOT 423
22.7.3 PRODUCT PORTFOLIO 424
22.7.4 RECENT DEVELOPMENTS 424
22.8 BD 425
22.8.1 COMPANY SNAPSHOT 425
22.8.2 REVENUE ANALYSIS 425
22.8.3 PRODUCT PORTFOLIO 426
22.8.4 RECENT DEVELOPMENT 426

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.